Effects of dextromethorphan on glial cell function: Proliferation, maturation, and protection from cytotoxic molecules

GLIA

Volumn 62, Issue 5, 2014, Pages 751-762

  Lisak, Robert P ^a   Nedelkoska, Liljana ^a   Benjamins, Joyce A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Multiple sclerosis; Neuroinflammation; Oligodendroglial progenitors; Protection; Sigma receptors

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CYTOTOXIC AGENT; DEXTROMETHORPHAN; GLUTAMIC ACID; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE; STAUROSPORINE; CYTOTOXIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CELL MATURATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; EXCITOTOXICITY; GLIA CELL; GLIAL CELL CULTURE; MACROGLIA; MICROGLIA; MOLECULE; MYELINATION; NERVE CELL LESION; NERVE FIBER; NERVOUS SYSTEM INFLAMMATION; NEWBORN PERIOD; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; REMYELINIZATION; STEM CELL; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL ENLARGEMENT; DOSE RESPONSE; DRUG EFFECTS; GLIA; PHYSIOLOGY; TOXICITY;

ANIMALS; CELL DIFFERENTIATION; CELL ENLARGEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXINS; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; NEUROGLIA; RATS;

EID: 84896319888     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22639     Document Type: Article

References (99)

1. Acar G, Idiman F, Idiman E, Kirkali G, Cakmakci H, Ozakbas S. 2003. Nitric oxide as an activity marker in multiple sclerosis. J Neurol 250:588-592.
2. Al-Saif A, Al-Mohanna F, Bohlega S. 2011. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 70:913-919.
3. Appel SH. 1993. Excitotoxic neuronal cell death in amyotrophic lateral sclerosis. Trends Neurosci 16:3-5.
4. Askmark H, Aquilonius SM, Gillberg PG, Liedholm LJ, Stalberg E, Wuopio R. 1993. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 56:197-200.
5. Bagayogo IP, Dreyfus CF. 2009. Regulated release of BDNF by cortical oligodendrocytes is mediated through metabotropic glutamate receptors and the PLC pathway. ASN Neuro 1:1.
6. Bansal R, Warrington AE, Gard AL, Ranscht B, Pfeiffer SE. 1989. Multiple and novel specificities of monoclonal antibodies O1, O4, and R- mAb used in the analysis of oligodendrocyte development. J Neurosci Res 24:548-557.
7. Bansal R, Winkler S, Bheddah S. 1999. Negative regulation of oligodendrocyte differentiation by galactosphingolipids. J Neurosci 19:7913-7924.
8. Barnham KJ, Masters CL, Bush AI. 2004. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3:205-214.
9. Beal MF. 2003. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 991:120-131.
10. Benjamins JA, Nedelkoska L, Bealmear B, Lisak RP. 2013. ACTH protects mature oligodendroglia from excitotoxic and inflammation-related damage in vitro. Glia 61:1206-1217.
11. Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y. 1994. Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 211:314-321.
12. Bisaga A, Kos T, Wojcikowski J, Daniel WA, Popik P. 2008. Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice. Drug Alcohol Depend 95(1-2):147-151.
13. Blin O, Azulay JP, Desnuelle C, Bille-Turc F, Braguer D, Besse D, Branger E, Crevat A, Serratrice G, Pouget JY. 1996. A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol 19:189-192.
14. Boggs JM, Gao W, Hirahara Y. 2008. Signal transduction pathways involved in interaction of galactosylceramide/sulfatide-containing liposomes with cultured oligodendrocytes and requirement for myelin basic protein and glycosphingolipids. J Neurosci Res 86:1448-1458.
15. Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, AVP-923 ALS Study Group. 2004. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology 63:1364-1370.
16. Butt AM. 2006. Neurotransmitter-mediated calcium signalling in oligodendrocyte physiology and pathology. Glia 54:666-675.
17. Calzada JI, Jones BE, Netland PA, Johnson DA. 2002. Glutamate-induced excitotoxicity in retina: Neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers. Neurochem Res 27(1-2):79-88.
18. Cammer W. 2001. Oligodendrocyte killing by quinolinic acid in vitro. Brain Res 896(1-2):157-160.
19. Chang A, Tourtellotte WW, Rudick R, Trapp BD. 2002. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346:165-173.
20. Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong JS, Deng W. 2011. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis 44:63-72.
21. Chen SL, Hsu KY, Huang EY, Lu RB, Tao PL. 2011. Low doses of dextromethorphan attenuate morphine-induced rewarding via the sigma-1 receptor at ventral tegmental area in rats. Drug Alcohol Depend 117(2-3):164-169.
22. De Biase LM, Kang SH, Baxi EG, Fukaya M, Pucak ML, Mishina M, Calabresi PA, Bergles DE. 2011. NMDA receptor signaling in oligodendrocyte progenitors is not required for oligodendrogenesis and myelination. J Neurosci 31:12650-12662.
23. DeCoster MA, Klette KL, Knight ES, Tortella FC. 1995. Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 671:45-53.
24. Dyer CA, Benjamins JA. 1990. Glycolipids and transmembrane signaling: Antibodies to galactocerebroside cause an influx of calcium in oligodendrocytes. J Cell Biol 111:625-633.
25. Ehret GB, Daali Y, Chabert J, Rebsamen M, Wolff A, Forster A, Moursli F, Fritschy D, Rossier MF, Piguet V, Dayer P, Gex-Fabry M, Desmeules JA. 2013. Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain. Pain Physician 16:45-56.
26. Estevez AG, Spear N, Manuel SM, Radi R, Henderson CE, Barbeito L, Beckman JS. 1998. Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation. J Neurosci 18:923-931.
27. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bredl M, van Horssen J, Lassmann H. 2012. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain Mar 135(Part 3):886-899.
28. Fujimoto M, Hayashi T, Urfer R, Mita S, Su TP. 2012. Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse 66:630-639.
29. Gao XF, Yao JJ, He YL, Hu C, Mei YA. 2012. Sigma-1 receptor agonists directly inhibit Nav1.2/1.4 channels. PLoS One 7:e49384.
30. Gonsette RE. 2008. Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. J Neurol Sci 274(1-2):48-53.
31. Gredal O, Werdelin L, Bak S, Christensen PB, Boysen G, Kristensen MO, Jesperson JM, Regeur L, Hinge HH, Jensen TS. 1997. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand 96:8-13.
32. Griesmaier E, Posod A, Gross M, Neubauer V, Wegleiter K, Hermann M, Urbanek M, Keller M, Kiechl-Kohlendorfer U. 2012. Neuroprotective effects of the sigma-1 receptor ligand PRE-084 against excitotoxic perinatal brain injury in newborn mice. Exp Neurol 237:388-395.
33. Gronier B, Debonnel G. 1999. Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol 368(2-3):183-196.
34. Guillemin GJ, Meininger V, Brew BJ. 2005. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis 2(3-4):166-176.
35. Guitart X, Codony X, Monroy X. 2004. Sigma receptors: Biology and therapeutic potential. Psychopharmacology (Berl) 174:301-319.
36. Guo F, Maeda Y, Ko EM, Delgado M, Horiuchi M, Soulika A, Meier L, Burns T, Itoh T, Shen H, Lee L, Sohn J, Pleasure D. 2012. Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development. J Neurosci 32:639-645.
37. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. 2011. Oxidative damage in multiple sclerosis lesions. Brain 134(Part 7):1914-1924.
38. Hall AA, Herrera Y, Ajmo CT Jr, Cuevas J, Pennypacker KR. 2009. Sigma receptors suppress multiple aspects of microglial activation. Glia 57:744-754.
39. Hart IK, Richardson WD, Heldin CH, Westermark B, Raff MC. 1989. PDGF receptors on cells of the oligodendrocyte-type-2 astrocyte (O-2A) cell lineage. Development 105:595-603.
40. Hayashi T, Su TP. 2004. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci USA 101:14949-14954.
41. Hayashi T, Su TP. 2007. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131:596-610.
42. Hayashi T, Hayashi E, Fujimoto M, Sprong H, Su TP. 2012. The lifetime of UDP-galactose: Ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperones. J Biol Chem 287:43156-43169.
43. Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL. 1994. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol 36:920-924.
44. Hooper DC, Ohnishi ST, Kean R, Numagami Y, Dietzschold B, Koprowski H. 1995. Local nitric oxide production in viral and autoimmune diseases of the central nervous system. Proc Natl Acad Sci USA 92:5312-5316.
45. Keller M, Griesmaier E, Auer M, Schlager G, Urbanek M, Simbruner G, Gressens P, Sarkozy G. 2008. Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain. Eur J Neurosci 27:874-883.
46. Kourrich S, Su TP, Fujimoto M, Bonci A. 2012. The sigma-1 receptor: Roles in neuronal plasticity and disease. Trends Neurosci 35:762-771.
47. Laroia N, McBride L, Baggs R, Guillet R. 1997. Dextromethorphan ameliorates effects of neonatal hypoxia on brain morphology and seizure threshold in rats. Brain Res Dev Brain Res 100:29-34.
48. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. 1997. Remyelination in multiple sclerosis. Mult Scler 3:133-136.
49. Lassmann H, van Horssen J. 2011. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 585:3715-3723.
50. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, Liu Y, Tsingalia A, Jin L, Zhang PW, Pellerini L, Magistretti PJ, Rothstein JD. 2012. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487:443-448.
51. Li C, Xiao L, Liu X, Yang W, Shen W, Hu C, Yang G, He C. 2013. A functional role of NMDA receptor in regulating the differentiation of oligodendrocyte precursor cells and remyelination. Glia 61:732-749.
52. Lisak RP, Benjamins JA, Bealmear B, Yao B, Land S, Nedelkoska L, Skundric D. 2006. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures. Mult Scler 12:149-168.
53. Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Yao B, Land S, Studzinski D. 2007. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: Neurotrophins, growth factors and structural proteins. J Neuroinflammation 4:30.
54. Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Studzinski D, Retland E, Yao B, Land S. 2009. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures. J Neuroinflammation 6:4.
55. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajesekharan S, Bar-Or A. 2012. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 246:85-95.
56. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Jong JS. 2003. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 305:212-218.
57. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 1999. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122(Part 12):2279-2295.
58. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination [see comments]. Ann Neurol 47:707-717.
59. Ludolph AC. 2013. Oligodendroglia: New players in amyotrophic lateral sclerosis. Brain 136(Part 2):370-371.
60. Luhmann HJ, Scheid M. 1994. Dextromethorphan attenuates hypoxia-induced neuronal dysfunction in rat neocortical slices. Neurosci Lett 178:171-174.
61. Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlstrom H, Sobow T, Maruszak A, Barcikowska M, Panegyres PK, Zekonowski C, Brooks WS, Williams KL, Blair IP, Mather KA, Sachdeu PS, Halliday GM, Schofield PR. 2010. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 68:639-649.
62. Marier JF, Deschênes JL, Hage A, Seliniotakis E, Gritsas A, Flarakos T, Beaudry F, Vachon P. 2005. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci 77:2911-2926.
63. Marier JF, Pope LE, Yakatan GJ, Berg JE, Stiles M, Vachon P. 2004. Influence of concomitant quinidine administration on dextromethorphan disposition in rats. J Vet Pharmacol Ther 27:111-114.
64. Maurice T, Su TP. 2009. The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195-206.
65. May PC. 1989. Selectivity of excitotoxic mechanisms in Alzheimer's disease. Neurobiol Aging 10:606-608; discussion 18-20.
66. Miller A, Panitch H. 2007. Therapeutic use of dextromethorphan: Key learnings from treatment of pseudobulbar affect. J Neurol Sci 259(1-2):67-73.
67. Nam Y, Shin EJ, Yang BK, Bach JH, Jeong JH, Chung YH, Park ES, Li Z, Kim KW, Kuon YB, Nabashima T, Kim HC. 2012. Dextromethorphan-induced psychotoxic behaviors cause sexual dysfunction in male mice via stimulation of sigma-1 receptors. Neurochem Int 61:913-922.
68. Nedelkoska L, Benjamins JA. 1998. Binding of cholera toxin B subunit: A surface marker for murine microglia but not oligodendrocytes or astrocytes. J Neurosci Res 53:605-612.
69. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, Smith T. 2008. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18:52-61.
70. Palacios G, Muro A, Vela JM, Molina-Holgado E, Guitart X, Ovalle S, Zamanillo D. 2003. Immunohistochemical localization of the sigma1-receptor in oligodendrocytes in the rat central nervous system. Brain Res 961:92-99.
71. Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler KN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A. 2006. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 59:780-787.
72. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorenson PS, Bruck W, Lucchinetti C, Lassmann H. 2006. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165-3172.
73. Philips T, Bento-Abreu A, Nonneman A, Haeck W, Staats K, Geelen V, Hersmus N, Kusters B, Van Den Bosch L, Van Damme P, Richardson WD, Robberecht W. 2013. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain 136(Part 2):471-482.
74. Pioro EP.2011. Current concepts in the pharmacotherapy of pseudobulbar affect. Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs 71:1193-1207.
75. Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R. 2010. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Safety, tolerability, and efficacy results trial of AVP-923 in PBA investigators. Ann Neurol 68:693-702.
76. Pitt D, Werner P, Raine CS. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6:67-70.
77. Pitt D, Nagelmeier IE, Wilson HC, Raine CS. 2003. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 61:1113-1120.
78. Pringle N, Collarini EJ, Hart IK, Raff MC, Richardson WD. 1991. Platelet-derived growth factor in central nervous system gliogenesis. Ann NY Acad Sci 633:160-168.
79. Rosen H. 2008. Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs Today (Barc) 44:661-668.
80. Rothstein JD, Martin LJ, Kuncl RW. 1992. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326:1464-1468.
81. Rothstein JD. 2009. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65:S3-S9.
82. Sas K, Robotka H, Toldi J, Vecsei L. 2007. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 257(1-2):221-239.
83. Scarpini E, Kreider BQ, Lisak RP, Pleasure DE. 1988. Establishment of Schwann cell cultures from adult rat peripheral nerves. Exp Neurol 102:167-176.
84. Sha S, Qu WJ, Li L, Lu ZH, Chen L, Yu WF. 2013. Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors. CNS Neurosci Ther 19:705-713.
85. Siu A, Drachtman R. 2007. Dextromethorphan: A review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev 13:96-106.
86. Smith KJ, Lassmann H. 2002. The role of nitric oxide in multiple sclerosis. Lancet Neurol 1:232-241.
87. Sommer I, Schachner M. 1981. Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: An immunocytological study in the central nervous system. Dev Biol 83:311-327.
88. Su TP, Hayashi T. 2003. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 10:2073-2080.
89. Thomas DM, Kuhn DM. 2005. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 1050(1-2):190-198.
90. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L. 2009. The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection. J Neurol Sci 283(1-2):21-27.
91. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. 1990. Sigma receptors: Biology and function. Pharmacol Rev 42:355-402.
92. Waxman SG. 2003. Nitric oxide and the axonal death cascade. Ann Neurol 53:150-153.
93. Weissman AD, McCann DJ, Lorden JF, Su TP. 1993. An absence of changes in sigma receptor subtypes in the brains of genetically dystonic (dt) rats. Eur J Pharmacol 250:329-332.
94. Werling LL, Lauterbach ED, Calef U. 2007. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist 13:272-294.
95. Werner P, Pitt D, Raine CS. 2001. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50:169-180.
96. Werner P, Pitt D, Raine CS. 2000. Glutamate excitotoxicity-A mechanism for axonal damage and oligodendrocyte death in multiple sclerosis? J Neural Transm Suppl 60:375-385.
97. Wong ML, Rettori V, al-Shekhlee A, Bongiorno PB, Canteros G, McCann SM, Gold PW, Licinio J. 1996. Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nat Med 2:581-584.
98. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. 1992. Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 51:647-655.
99. Zipp F. 2000. Apoptosis in multiple sclerosis. Cell Tissue Res 301:163-171.